The role of P-glycoprotein in psychiatric disorders: A reliable guard of the brain?

Central Nervous System Agents in Medicinal Chemistry

Volumn 11, Issue 3, 2011, Pages 197-209

  de Klerk, Onno L ^a,b   Bosker, Fokko J ^a   Luurtsema, Gert ^a   Nolte, Ilja M ^c   Dierckx, Rudi ^a   den Boer, Johan A ^a   Potschka, Heidrun ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Psychiatric Hospital GGZ Drenthe   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidepressive agents; Antipsychotic agents; Blood brain barrier; Major depressive disorder; P glycoprotein; Schizophrenia

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUPENTIXOL; FLUVOXAMINE; GLYCOPROTEIN P; HALOPERIDOL; LAMOTRIGINE; MOOD STABILIZER; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PEROSPIRONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; UNINDEXED DRUG; VALPROIC ACID; VALSPODAR; VENLAFAXINE;

AGING; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN; DEPRESSION; DRUG BIOAVAILABILITY; HUMAN; MAJOR DEPRESSION; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; MENTAL DISEASE; MOLECULAR IMAGING; MOLECULAR MODEL; MOOD DISORDER; NERVE DEGENERATION; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; TREATMENT RESPONSE;

EID: 80055107174     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152411798047744     Document Type: Article

References (137)

1. Bernacki, J.; Dobrowolska, A.; Nierwinska, K.; Malecki, A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol. Rep., 2008, 60 (5), 600-622.
2. Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 57 (2), 173-185.
3. Linnet, K.; Ejsing, T.B. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol., 2008, 18 (3), 157-169.
4. Liu, X.; Chen, C.; Smith, B.J. Progress in brain penetration evaluation in drug discovery and development. J. Pharmacol. Exp. Ther., 2008, 325 (2), 349-356.
5. Juliano, R.L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Bio-phys. Acta, 1976, 455 (1), 152-162.
6. Sharom, F.J. Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Bio-chem. Cell Biol., 2006, 84 (6), 979-992.
7. Rao, V.V.; Dahlheimer, J.L.; Bardgett, M.E.; Snyder, A.Z.; Finch, R.A.; Sartorelli, A.C.; Piwnica-Worms, D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl. Acad. Sci. USA, 1999, 96 (7), 3900-3905.
8. Lazarowski, A.; Massaro, M.; Schteinschnaider, A.; Intruvini, S.; Sevlever, G.; Rabinowicz, A. Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy. Ther. Drug Monit., 2004, 26 (1), 44-46.
9. Volk, H.A.; Burkhardt, K.; Potschka, H.; Chen, J.; Becker, A.; Loscher, W. Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuro-science, 2004, 123 (3), 751-759.
10. Aronica, E.; Gorter, J.A.; Jansen, G.H.; van Veelen, C.W.; van Rijen, P.C.; Leenstra, S.; Ramkema, M.; Scheffer, G.L.; Scheper, R.J.; Troost, D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neuro-science, 2003, 118 (2), 417-429.
11. Banerjee, S.; Bhat, M.A. Neuron-glial interactions in blood-brain barrier formation. Annu. Rev. Neurosci., 2007, 30, 235-258.
12. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323 (5922), 1718-1722.
13. Kannan, P.; John, C.; Zoghbi, S.S.; Halldin, C.; Gottesman, M.M.; Innis, R.B.; Hall, M.D. Imaging the Function of P-Glycoprotein With Radiotracers: Pharmacokinetics and In Vivo Applications. Clin. Pharmacol. Ther., 2009, 86 (4), 368-377.
14. Lubberink, M.; Luurtsema, G.; van Berckel, B.N.; Boellaard, R.; Toornvliet, R.; Windhorst, A.D.; Franssen, E.J.; Lammertsma, A.A. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J. Cereb. Blood Flow Metab., 2007, 27 (2), 424-433.
15. Elsinga, P.H.; Hendrikse, N.H.; Bart, J.; van Waarde, A.; Vaalburg, W. Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain. Mol. Imaging Biol., 2005, 7 (1), 37-44.
16. Hendrikse, N.H.; Schinkel, A.H.; de Vries, E.G.; Fluks, E.; van der Graaf, W.T.; Willemsen, A.T.; Vaalburg, W.; Franssen, E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol., 1998, 124 (7), 1413-1418.
17. Seneca, N.; Zoghbi, S.S.; Liow, J.S.; Kreisl, W.; Herscovitch, P.; Jenko, K.; Gladding, R.L.; Taku, A.; Pike, V.W.; Innis, R.B. Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein. J. Nucl. Med., 2009, 50 (5), 807-813.
18. Lee, Y.J.; Maeda, J.; Kusuhara, H.; Okauchi, T.; Inaji, M.; Nagai, Y.; Obayashi, S.; Nakao, R.; Suzuki, K.; Sugiyama, Y.; Suhara, T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil. J. Pharmacol. Exp. Ther., 2006, 316 (2), 647-653.
19. Sasongko, L.; Link, J.M.; Muzi, M.; Mankoff, D.A.; Yang, X.; Collier, A.C.; Shoner, S.C.; Unadkat, J.D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther., 2005, 77 (6), 503-514.
20. Syvanen, S.; Hammarlund-Udenaes, M. Using PET Studies of P-gp Function to Elucidate Mechanisms Underlying the Disposition of Drugs. Curr. Top. Med. Chem., 2010, 10 (17), 1799-1809.
21. Wagner, C.C.; Bauer, M.; Karch, R.; Feurstein, T.; Kopp, S.; Chi-ba, P.; Kletter, K.; Loscher, W.; Muller, M.; Zeitlinger, M.; Langer, O. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl. Med., 2009, 50 (12), 1954-1961.
22. Maines, L.W.; Antonetti, D.A.; Wolpert, E.B.; Smith, C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clo-zapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacol., 2005, 49 (5), 610-617.
23. Störmer, E.; von Moltke, L.L.; Perloff, M.D.; Greenblatt, D.J. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J. Clin. Pharmacol., 2001, 41 (7), 708-714.
24. Szabo, D.; Szabo, G., Jr.; Ocsovszki, I.; Aszalos, A.; Molnar, J. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett., 1999, 139 (1), 115-119.
25. Weber, C.C.; Kressmann, S.; Ott, M.; Fricker, G.; Muller, W.E. Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry, 2005, 38 (6), 293-300.
26. Weiss, J.; Dormann, S.M.; Martin-Facklam, M.; Kerpen, C.J.; Ketabi-Kiyanvash, N.; Haefeli, W.E. Inhibition of P-glycoprotein by newer antidepressants. J. Pharmacol. Exp. Ther., 2003, 305 (1), 197-204.
27. Achira, M.; Suzuki, H.; Ito, K.; Sugiyama, Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cyto-chrome P4503A4. AAPS. PharmSci., 1999, 1 (4), E18.
28. Wang, J.S.; Zhu, H.J.; Markowitz, J.S.; Donovan, J.L.; DeVane, C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacol. (Berl), 2006, 187 (4), 415-423.
29. El Ela, A.A.; Hartter, S.; Schmitt, U.; Hiemke, C.; Spahn-Langguth, H.; Langguth, P. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J. Pharm. Pharmacol., 2004, 56 (8), 967-975.
30. Baltes, S.; Gastens, A.M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Loscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacol., 2007, 52 (2), 333-346.
31. Doran, A.; Obach, R.S.; Smith, B.J.; Hosea, N.A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L.M.; Gibbs, J.P.; Gibbs, M.A.; Hatch, H.; Hop, C.E.; Kasman, I.N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F.M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D.K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J.W.; Venkatakrishnan, K.; Walens, G.; Wang, E.Q.; Wong, D.; Yasgar, A.S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos., 2005, 33 (1), 165-174.
32. Ejsing, T.B.; Hasselstrom, J.; Linnet, K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol. Drug Interact., 2006, 21 (3-4), 139-162.
33. Uhr, M.; Steckler, T.; Yassouridis, A.; Holsboer, F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacol., 2000, 22 (4), 380-387.
34. Uhr, M.; Grauer, M.T. Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res., 2003, 37 (3), 179-185.
35. Uhr, M.; Grauer, M.T.; Holsboer, F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry, 2003, 54 (8), 840-846.
36. Ejsing, T.B.; Pedersen, A.D.; Linnet, K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knockout mice and in drug-drug interaction experiments. Hum. Psycho-pharmacol., 2005, 20 (7), 493-500.
37. Kirschbaum, K.M.; Henken, S.; Hiemke, C.; Schmitt, U. Pharma-codynamic consequences of P-glycoprotein-dependent pharma-cokinetics of risperidone and haloperidol in mice. Behav. Brain Res., 2008, 188 (2), 298-303.
38. Schinkel, A.H.; Wagenaar, E.; Mol, C.A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 1996, 97 (11), 2517-2524.
39. Wang, J.S.; Zhu, H.J.; Donovan, J.L.; Yuan, H.J.; Markowitz, J.S.; Geesey, M.E.; DeVane, C.L. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr. Res., 2009, 110 (1-3), 90-94.
40. Wang, J.S.; Taylor, R.; Ruan, Y.; Donovan, J.L.; Markowitz, J.S.; Lindsay De Vane, C. Olanzapine Penetration into Brain is Greater in Transgenic Abcb1a P-glycoprotein-Deficient Mice than FVB1 (Wild-Type) Animals. Neuropsychopharmacol., 2003, 29 (3), 551-557.
41. Wang, J.S.; Ruan, Y.; Taylor, R.M.; Donovan, J.L.; Markowitz, J.S.; DeVane, C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol., 2004, 7 (04), 415-419.
42. Peer, D.; Dekel, Y.; Melikhov, D.; Margalit, R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res., 2004, 64 (20), 7562-7569.
43. Wang, J.S.; Zhu, H.J.; Gibson, B.B.; Markowitz, J.S.; Donovan, J.L.; DeVane, C.L. Sertraline and its metabolite desmethylser-traline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol. Pharm. Bull., 2008, 31 (2), 231-234.
44. Luna-Tortos, C.; Fedrowitz, M.; Loscher, W. Several major antie-pileptic drugs are substrates for human P-glycoprotein. Neuro-pharmacol., 2008, 55 (8), 1364-1375.
45. Grauer, M.T.; Uhr, M. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J. Psychopharmacol., 2004, 18 (1), 66-74.
46. Kirschbaum, K.M.; Uhr, M.; Holthoewer, D.; Namendorf, C.; Pietrzik, C.; Hiemke, C.; Schmitt, U. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neu-ropharmacol., 2010, 59 (6), 474-479.
47. Uhr, M.; Grauer, M.T.; Yassouridis, A.; Ebinger, M. Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J. Psychiatr. Res., 2007, 41 (1-2), 179-188.
48. Miura, M.; Uno, T.; Tateishi, T.; Suzuki, T. Pharmacokinetics of fexofenadine enantiomers in healthy subjects. Chirality, 2007, 19 (3), 223-227.
49. Fromm, M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol. Sci., 2004, 25 (8), 423-429.
50. Zhou, S.F.; Wang, L.L.; Di, Y.M.; Xue, C.C.; Duan, W.; Li, C.G.; Li, Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr. Med. Chem., 2008, 15 (20), 1981-2039.
51. Gelisse, P.; Hillaire-Buys, D.; Halaili, E.; Jean-Pastor, M.J.; Vespignan, H.; Coubes, P.; Crespel, A. [Carbamazepine and clarithromycin: a clinically relevant drug interaction] Rev. Neurol. (Paris), 2007, 163 (11), 1096-1099.
52. Jover, F.; Cuadrado, J.M.; Andreu, L.; Merino, J. Reversible coma caused by risperidone-ritonavir interaction. Clin. Neuropharmacol., 2002, 25 (5), 251-253.
53. Sheehan, N.L.; Brouillette, M.J.; Delisle, M.S.; Allan, J. Possible interaction between lopinavir/ritonavir and valproic Acid exacerbates bipolar disorder. Ann. Pharmacother., 2006, 40 (1), 147-150.
54. Karssen, A.M.; Meijer, O.C.; van der Sandt, I.; Lucassen, P.J.; de Lange, E.C.; de Boer, A.G.; de Kloet, E.R. Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticoster-one to mouse and human brain. Endocrinology, 2001, 142 (6), 2686-2694.
55. Ueda, K.; Okamura, N.; Hirai, M.; Tanigawara, Y.; Saeki, T.; Kio-ka, N.; Komano, T.; Hori, R. Human P-glycoprotein transports cor-tisol, aldosterone, and dexamethasone, but not progesterone. J. Biol. Chem., 1992, 267 (34), 24248-24252.
56. Holsboer, F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacol., 2000, 23 (5), 477-501.
57. Pariante, C.M.; Makoff, A.; Lovestone, S.; Feroli, S.; Heyden, A.; Miller, A.H.; Kerwin, R.W. Antidepressants enhance glucocorti-coid receptor function in vitro by modulating the membrane steroid transporters. Br. J. Pharmacol., 2001, 134 (6), 1335-1343.
58. Weber, C.C.; Eckert, G.P.; Muller, W.E. Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsycho-pharmacol., 2006, 31 (11), 2443-2448.
59. Mason, B.L.; Pariante, C.M.; Jamel, S.; Thomas, S.A. Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers and nonbarrier regions. Endocrinology, 2010, 151 (11), 5294-5305.
60. Murck, H. Magnesium and affective disorders. Nutr. Neurosci., 2002, 5 (6), 375-389.
61. 2+. Bioorg. Med Chem., 2009, 17 (6), 2423-2427.
62. Ambroziak, K.; Kuteykin-Teplyakov, K.; Luna-Tortos, C.; Al-Falah, M.; Fedrowitz, M.; Loscher, W. Exposure to antiepileptic drugs does not alter the functionality of P-glycoprotein in brain capillary endothelial and kidney cell lines. Eur. J. Pharmacol, 2010, 628 (1-3), 57-66.
63. Lombardo, L.; Pellitteri, R.; Balazy, M.; Cardile, V. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr. Neurovasc. Res, 2008, 5 (2), 82-92.
64. Yang, H.W.; Liu, H.Y.; Liu, X.; Zhang, D.M.; Liu, Y.C.; Liu, X.D.; Wang, G.J.; Xie, L. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci. Lett., 2008, 434 (3), 299-303.
65. Sukhai, M.; Piquette-Miller, M. Regulation of the multidrug resistance genes by stress signals. J.Pharm. Pharm. Sci., 2000, 3 (2), 268-280.
66. Schiepers, O.J.; Wichers, M.C.; Maes, M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29 (2), 201-217.
67. McRae, M.P.; Brouwer, K.L.; Kashuba, A.D. Cytokine regulation of P-glycoprotein. Drug Metab Rev., 2003, 35 (1), 19-33.
68. Roberts, D.J.; Goralski, K.B. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert. Opin. Drug Metab. Toxicol., 2008, 4 (10), 1245-1264.
69. Hartz, A.M.; Bauer, B.; Fricker, G.; Miller, D.S. Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. Mol. Pharmacol., 2004, 66 (3), 387-394.
70. Hartz, A.M.; Bauer, B.; Fricker, G.; Miller, D.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol., 2006, 69 (2), 462-470.
71. Tan, K.H.; Purcell, W.M.; Heales, S.J.; McLeod, J.D.; Hurst, R.D. Evaluation of the role of P-glycoprotein in inflammation induced blood-brain barrier damage. Neuroreport, 2002, 13 (18), 2593-2597.
72. Gomez-Gonzalez, B.; Escobar, A. Altered functional development of the blood-brain barrier after early life stress in the rat. Brain Res. Bull., 2009, 79 (6), 376-387.
73. Sinton, C.M.; Fitch, T.E.; Petty, F.; Haley, R.W. Stressful Manipulations That Elevate Corticosterone Reduce Blood-Brain Barrier Permeability to Pyridostigmine in the Rat. Toxicol- Appl. Pharmacol., 2000, 165 (1), 99-105.
74. Chandler, N.; Jacobson, S.; Esposito, P.; Connolly, R.; Theoha-rides, T.C. Acute stress shortens the time to onset of experimental allergic encephalomyelitis in SJL/J mice. Brain, Behav. Immun., 2002, 16 (6), 757-763.
75. Esposito, P.; Jacobson, S.; Connolly, R.; Gheorghe, D.; Theoha-rides, T.C. Non-invasive assessment of blood-brain barrier (BBB) permeability using a gamma camera to detect 99technetium-gluceptate extravasation in rat brain. Brain Res. Protocols, 2001, 8 (2), 143-149.
76. Gudmundsson, P.; Skoog, I.; Waern, M.; Blennow, K.; Palsson, S.; Rosengren, L.; Gustafson, D. The relationship between cerebrospi-nal fluid biomarkers and depression in elderly women. Am. J. Geriatr. Psychiatry, 2007, 15 (10), 832-838.
77. Thoeringer, C.K.; Wultsch, T.; Shahbazian, A.; Painsipp, E.; Hol-zer, P. Multidrug-resistance gene 1-type p-glycoprotein (MDR1 pgp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. Psychoneuroendocrinology, 2009, 32 (8-10), 1028-1040.
78. de Klerk, O.L.; Willemsen, A.T.; Bosker, F.J.; Bartels, A.L.; Hen-drikse, N.H.; den Boer, J.A.; Dierckx, R.A. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res., 2010, 183 (2), 151-156.
79. 11C]verapamil as a probe for P-glycoprotein function in the blood?brain barrier. Int. J. Neuropsychopharmacol., 2009, 12 (07), 895-904.
80. de Klerk, O.L.; Bosker, F.J.; Willemsen, A.T.; van Waarde, A.; Visser, A.K.; de Jager T.; Dagyte, G.; den Boer, J.A.; Dierckx, R.A.; Meerlo, P. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J. Psychopharmacol., 2010, 24 (8), 1237-1242.
81. Maes, M.; Yirmyia, R.; Noraberg, J.; Brene, S.; Hibbeln, J.; Perini, G.; Kubera, M.; Bob, P.; Lerer, B.; Maj, M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis., 2009, 24 (1), 27-53.
82. Bartels, A.L.; Willemsen, A.T.; Kortekaas, R.; de Jong, B.M.; de Vries, R.; de Klerk, O.; van Oostrom, J.C.; Portman, A.; Leenders, K.L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J. Neural Transm., 2008, 115 (7), 1001-1009.
83. Bartels, A.L.; Kortekaas, R.; Bart, J.; Willemsen, A.T.; de Klerk, O.L.; de Vries, J.J.; van Oostrom, J.C.; Leenders, K.L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration. Neu-robiol. Aging, 2008.
84. Bauer, M.; Karch, R.; Neumann, F.; Abrahim, A.; Wagner, C.; Kletter, K.; Mller, M.; Zeitlinger, M.; Langer, O. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur. J. Clin. Pharmacol., 2009, 65 (9), 941-946.
85. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Koretz, D.; Meri-kangas, K.R.; Rush, A.J.; Walters, E.E.; Wang, P.S. The epidemiology of major depressive disorder: results from the National Co-morbidity Survey Replication (NCS-R). JAMA, 2003, 289 (23), 3095-3105.
86. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brockmol-ler, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 2000, 97 (7), 3473-3478.
87. Dong, C.; Wong, M.L.; Licinio, J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol. Psychiatry, 2009, 14 (12), 1105-1118.
88. Qian, W.; Homma, M.; Itagaki, F.; Tachikawa, H.; Kawanishi, Y.; Mizukami, K.; Asada, T.; Inomata, S.; Honda, K.; Ohkohchi, N.; Kohda, Y. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol. Pharm. Bull., 2006, 29 (12), 2446-2450.
89. Kuzman, M.R.; Medved, V.; Bozina, N.; Hotujac, L.; Sain, I.; Bilusic, H. The influence of 5-HT (2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res., 2008, 160 (3), 308-315.
90. Xing, Q.; Gao, R.; Li, H.; Feng, G.; Xu, M.; Duan, S.; Meng, J.; Zhang, A.; Qin, S.; He, L. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics, 2006, 7 (7), 987-993.
91. Zhao, R.; Raub, T.J.; Sawada, G.A.; Kasper, S.C.; Bacon, J.A.; Bridges, A.S.; Pollack, G.M. Breast Cancer Resistance Protein Interacts with Various Compounds in Vitro, but Plays a Minor Role in Substrate Efflux at the Blood-Brain Barrier. Drug Metabolism and Disposition, 2009, 37 (6), 1251-1258.
92. Cooray, H.C.; Blackmore, C.G.; Maskell, L.; Barrand, M.A. Localisation of breast cancer resistance protein in microvessel endothe-lium of human brain. Neuroreport, 2002, 13 (16), 2059-2063.
93. Zhang, Y.; Schuetz, J.D.; Elmquist, W.F.; Miller, D.W. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J. Pharmacol. Exp. Ther., 2004, 311 (2), 449-455.
94. Warren, M.S.; Zerangue, N.; Woodford, K.; Roberts, L.M.; Tate, E.H.; Feng, B.; Li, C.; Feuerstein, T.J.; Gibbs, J.; Smith, B.; de Mo-rais, S.M.; Dower, W.J.; Koller, K.J. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol. Res., 2009, 59 (6), 404-413.
95. Slot, A.J.; Wise, D.D.; Deeley, R.G.; Monks, T.J.; Cole, S.P. Modulation of human multidrug resistance protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) transport activities by endogenous and exogenous glutathione-conjugated catechol metabolites. Drug Metab. Dispos., 2008, 36 (3), 552-560.
96. Pedersen, J.M.; Matsson, P.; Bergstrom, C.A.; Norinder, U.; Hoog-straate, J.; Artursson, P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter actions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem., 2008, 51 (11), 3275-3287.
97. Okamura, T.; Kikuchi, T.; Okada, M.; Toramatsu, C.; Fukushi, K.; Takei, M.; Irie, T. Noninvasive and quantitative assessment of the function of multidrug resistance-associated protein 1 in the living brain. J. Cereb. Blood Flow Metab., 2009, 29 (3), 504-511.
98. Matsson, P.; Englund, G.; Ahlin, G.; Bergstrom, C.A.; Norinder, U.; Artursson, P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J. Pharmacol. Exp. Ther., 2007, 323 (1), 19-30.
99. Matsson, P.; Pedersen, J.M.; Norinder, U.; Bergstrom, C.A.; Ar-tursson, P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res., 2009, 26 (8), 1816-1831.
100. Urquhart, B.L.; Kim, R.B. Blood-brain barrier transporters and response to CNS-active drugs. Eur.J Clin. Pharmacol., 2009, 65 (11), 1063-1070.
101. Rochat, B.; Baumann, P.; Audus, K.L. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res., 1999, 831 (1-2), 229-236.
102. Ruike, Z.; Junhua, C.; Wenxing, P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum. Psychopharma-col., 2010, 25 (7-8), 553-559.
103. Feng, B.; Mills, J.B.; Davidson, R.E.; Mireles, R.J.; Janiszewski, J.S.; Troutman, M.D.; de Morais, S.M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos., 2008, 36 (2), 268-275.
104. Oganesian, A.; Shilling, A.D.; Young-Sciame, R.; Tran, J.; Watan-yar, A.; Azam, F.; Kao, J.; Leung, L. Desvenlafaxine and ven-lafaxine exert minimal in vitro inhibition of human cytochrome p450 and p-glycoprotein activities. Psychopharmacol. Bull., 2009, 42 (2), 47-63.
105. Wu, J.; Sha, X.Y.; Fang, X.L. Transport of aripiprazole across Caco-2 monolayer model. Yao Xue. Xue. Bao., 2009, 44 (2), 188-191.
106. Kirschbaum, K.M.; Uhr, M.; Holthoewer, D.; Namendorf, C.; Pietrzik, C.; Hiemke, C.; Schmitt, U. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neu-ropharmacology, 2010, 59 (6), 474-479.
107. Boulton, D.W.; DeVane, C.L.; Liston, H.L.; Markowitz, J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsy-chotics. Life Sci., 2002, 71 (2), 163-169.
108. Wang, E.j.; Lew, K.; Barecki, M.; Casciano, C.N.; Clement, R.P.; Johnson, W.W. Quantitative Distinctions of Active Site Molecular Recognition by P-Glycoprotein and Cytochrome P450 3A4. Chem. Res. Toxicology, 2001, 14 (12), 1596-1603.
109. Iwaki, K.; Sakaeda, T.; Kakumoto, M.; Nakamura, T.; Komoto, C.; Okamura, N.; Nishiguchi, K.; Shiraki, T.; Horinouchi, M.; Oku-mura, K. Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein. J. Pharm. Pharmacol., 2006, 58 (12), 1617-1622.
110. Zhou, Y.G.; Li, K.Y.; Li, H.D. Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells. Eur. J. Clin. Pharmacol., 2008, 64 (7), 697-703.
111. Zhu, H.J.; Wang, J.S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B.; DeVane, C.L. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology, 2007, 32 (4), 757-764.
112. Mahar Doan, K.M.; Humphreys, J.E.; Webster, L.O.; Wring, S.A.; Shampine, L.J.; Serabjit-Singh, C.J.; Adkison, K.K.; Polli, J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther., 2002, 303 (3), 1029-1037.
113. Weiss, J.; Kerpen, C.J.; Lindenmaier, H.; Dormann, S.M.; Haefeli, W.E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther., 2003, 307 (1), 262-267.
114. Yang, H.W.; Liu, H.Y.; Liu, X.; Zhang, D.M.; Liu, Y.C.; Liu, X.D.; Wang, G.J.; Xie, L. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci. Lett., 2008, 434 (3), 299-303.
115. Rizzi, M.; Caccia, S.; Guiso, G.; Richichi, C.; Gorter, J.A.; Aronica, E.; Aliprandi, M.; Bagnati, R.; Fanelli, R.; D'Incalci, M.; Samanin, R.; Vezzani, A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J. Neurosci., 2002, 22 (14), 5833-5839.
116. Sills, G.J.; Kwan, P.; Butler, E.; de Lange, E.C.; van den Berg, D.J.; Brodie, M.J. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Be-hav., 2002, 3 (5), 427-432.
117. Rivers, F.; O'Brien, T.J.; Callaghan, R. Exploring the possible interaction between anti-epilepsy drugs and multidrug efflux pumps; in vitro observations. Eur. J. Pharmacol., 2008, 598 (1-3), 1-8.
118. Potschka, H.; Fedrowitz, M.; Loscher, W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett., 2002, 327 (3), 173-176.
119. Sills, G.J.; Kwan, P.; Butler, E.; de Lange, E.C.; van den Berg, D.J.; Brodie, M.J. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Be-hav., 2002, 3 (5), 427-432.
120. Baltes, S.; Fedrowitz, M.; Tortos, C.L.; Potschka, H.; Loscher, W. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther., 2007, 320 (1), 331-343.
121. Yang, H.W.; Liu, H.Y.; Liu, X.; Zhang, D.M.; Liu, Y.C.; Liu, X.D.; Wang, G.J.; Xie, L. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci. Lett., 2008, 434 (3), 299-303.
122. Laika, B.; Leucht, S.; Steimer, W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin. Chem., 2006, 52 (5), 893-895.
123. Uhr, M.; Tontsch, A.; Namendorf, C.; Ripke, S.; Lucae, S.; Ising, M.; Dose, T.; Ebinger, M.; Rosenhagen, M.; Kohli, M.; Kloiber, S.; Salyakina, D.; Bettecken, T.; Specht, M.; Putz, B.; Binder, E.B.; Muller-Myhsok, B.; Holsboer, F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron, 2008, 57 (2), 203-209.
124. Sarginson, J.E.; Lazzeroni, L.C.; Ryan, H.S.; Ershoff, B.D.; Schatzberg, A.F.; Murphy, G.M., Jr. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Phar-macogenet. Genomics, 2010, 20 (8), 467-475.
125. Kato, M.; Fukuda, T.; Serretti, A.; Wakeno, M.; Okugawa, G.; Ikenaga, Y.; Hosoi, Y.; Takekita, Y.; Mandelli, L.; Azuma, J.; Ki-noshita, T. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32 (2), 398-404.
126. Mihaljevic, P.A.; Bozina, N.; Sagud, M.; Rojnic, K.M.; Lovric, M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog. Neuropsychopharma-col. Biol. Psychiatry, 2008, 32 (6), 1439-1444.
127. Perlis, R.H.; Fijal, B.; Dharia, S.; Heinloth, A.N.; Houston, J.P. Failure to Replicate Genetic Associations with Antidepressant Treatment Response in Duloxetine-Treated Patients. Biol. Psychiatry, 2010, 67 (11), 1110-3.
128. Peters, E.J.; Slager, S.L.; Kraft, J.B.; Jenkins, G.D.; Reinalda, M.S.; McGrath, P.J.; Hamilton, S.P. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS. One., 2008, 3 (4), e1872.
129. Lin, K.M.; Chiu, Y.F.; Tsai, I.J.; Chen, C.H.; Shen, W.W.; Liu, S.C.; Lu, S.C.; Liu, C.Y.; Hsiao, M.C.; Tang, H.S.; Liu, S.I.; Chang, L.H.; Wu, C.S.; Tsou, H.H.; Tsai, M.H.; Chen, C.Y.; Wang, S.M.; Kuo, H.W.; Hsu, Y.T.; Liu, Y.L. ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenetics and Genomics, 2011, 21 (4), 163-170.
130. Roberts, R.L.; Joyce, P.R.; Mulder, R.T.; Begg, E.J.; Kennedy, M.A. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J., 2002, 2 (3), 191-196.
131. Lin, Y.C.; Ellingrod, V.L.; Bishop, J.R.; Miller, D. The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia. Ther. Drug Monit., 2006, 28 (5), 668-672.
132. Jovanovic, N.; Bozina, N.; Lovric, M.; Medved, V.; Jakovljevic, M.; Peles, A.M. The role of CYP2D6 and ABCB1 pharmacogenet-ics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol., 2010, 66 (11), 1109-1117.
133. Sirot Jacqenoud, E.M.; Knezevic, B.M.; Morena, G.P.M.; Haren-berg, S.P.; Oneda, B.P.; Crettol, S.P.; Ansermot, N.P.; Baumann, P.P.; Eap, C.B.P. ABCB1 and Cytochrome P450 Polymorphisms: Clinical Pharmacogenetics of Clozapine. J. Clin. Psychopharma-cology, 2009, 29 (4), 319-326.
134. Fukui, N.; Suzuki, Y.; Sawamura, K.; Sugai, T.; Watanabe, J.; Inoue, Y.; Someya, T. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther. Drug Monit., 2007, 29 (2), 185-189.
135. Ghotbi, R.; Mannheimer, B.; Aklillu, E.; Suda, A.; Bertilsson, L.; Eliasson, E.; Ûsby, U. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposureGÇöan impact similar to male gender or smoking in schizophrenic patients. Eur. J. Clin. Pharmacol., 2010, 66 (5), 465-74.
136. Jovanovic, N.; Bozina, N.; Lovric, M.; Medved, V.; Jakovljevic, M.; Peles, A.M. The role of CYP2D6 and ABCB1 pharmacogenet-ics in drug-naive patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol., 2010, 66 (11), 1109-1117.
137. Yasui-Furukori, N.; Mihara, K.; Takahata, T.; Suzuki, A.; Naka-gami, T.; De, V.R.; Tateishi, T.; Kondo, T.; Kaneko, S. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br. J. Clin. Pharmacol., 2004, 57 (5), 569-575.